These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 32277872)

  • 1. Heat-inactivated Bifidobacterium bifidum MIMBb75 (SYN-HI-001) in the treatment of irritable bowel syndrome: a multicentre, randomised, double-blind, placebo-controlled clinical trial.
    Andresen V; Gschossmann J; Layer P
    Lancet Gastroenterol Hepatol; 2020 Jul; 5(7):658-666. PubMed ID: 32277872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomised clinical trial: Bifidobacterium bifidum MIMBb75 significantly alleviates irritable bowel syndrome and improves quality of life--a double-blind, placebo-controlled study.
    Guglielmetti S; Mora D; Gschwender M; Popp K
    Aliment Pharmacol Ther; 2011 May; 33(10):1123-32. PubMed ID: 21418261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Faecal microbiota transplantation for diarrhoea-predominant irritable bowel syndrome: a double-blind, randomised, placebo-controlled trial.
    Aroniadis OC; Brandt LJ; Oneto C; Feuerstadt P; Sherman A; Wolkoff AW; Kassam Z; Sadovsky RG; Elliott RJ; Budree S; Kim M; Keller MJ
    Lancet Gastroenterol Hepatol; 2019 Sep; 4(9):675-685. PubMed ID: 31326345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faecal microbiota transplantation versus placebo for moderate-to-severe irritable bowel syndrome: a double-blind, randomised, placebo-controlled, parallel-group, single-centre trial.
    Johnsen PH; Hilpüsch F; Cavanagh JP; Leikanger IS; Kolstad C; Valle PC; Goll R
    Lancet Gastroenterol Hepatol; 2018 Jan; 3(1):17-24. PubMed ID: 29100842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effectiveness of Synbiotic Preparation Containing
    Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kosikowski W; Szczerbiński M; Gantzel J; Cukrowska B
    Nutrients; 2020 Jul; 12(7):. PubMed ID: 32635661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of Bifidobacterium quadruple viable tablet in the treatment of diarrhea predominant irritable bowel syndrome: protocol for a randomized, double-blind, placebo-controlled, multicenter trial.
    Bai T; Zeng H; Long Y; Li X; Sun X; Lan Y; Gao L; Zhang L; Feng Z; Hou X
    Trials; 2020 Jun; 21(1):597. PubMed ID: 32605578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Yoon JS; Sohn W; Lee OY; Lee SP; Lee KN; Jun DW; Lee HL; Yoon BC; Choi HS; Chung WS; Seo JG
    J Gastroenterol Hepatol; 2014 Jan; 29(1):52-9. PubMed ID: 23829297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double blind randomized controlled trial of a probiotic combination in 100 patients with irritable bowel syndrome.
    Drouault-Holowacz S; Bieuvelet S; Burckel A; Cazaubiel M; Dray X; Marteau P
    Gastroenterol Clin Biol; 2008 Feb; 32(2):147-52. PubMed ID: 18387426
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Martoni CJ; Srivastava S; Leyer GJ
    Nutrients; 2020 Jan; 12(2):. PubMed ID: 32019158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized double-blind placebo-controlled clinical trial on efficacy and safety of association of simethicone and Bacillus coagulans (Colinox®) in patients with irritable bowel syndrome.
    Urgesi R; Casale C; Pistelli R; Rapaccini GL; de Vitis I
    Eur Rev Med Pharmacol Sci; 2014; 18(9):1344-53. PubMed ID: 24867512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome.
    Whorwell PJ; Altringer L; Morel J; Bond Y; Charbonneau D; O'Mahony L; Kiely B; Shanahan F; Quigley EM
    Am J Gastroenterol; 2006 Jul; 101(7):1581-90. PubMed ID: 16863564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Diet Low in FODMAPs Reduces Symptoms in Patients With Irritable Bowel Syndrome and A Probiotic Restores Bifidobacterium Species: A Randomized Controlled Trial.
    Staudacher HM; Lomer MCE; Farquharson FM; Louis P; Fava F; Franciosi E; Scholz M; Tuohy KM; Lindsay JO; Irving PM; Whelan K
    Gastroenterology; 2017 Oct; 153(4):936-947. PubMed ID: 28625832
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized placebo-controlled clinical trial of a multi-strain probiotic formulation (Bio-Kult®) in the management of diarrhea-predominant irritable bowel syndrome.
    Ishaque SM; Khosruzzaman SM; Ahmed DS; Sah MP
    BMC Gastroenterol; 2018 May; 18(1):71. PubMed ID: 29801486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amitriptyline at Low-Dose and Titrated for Irritable Bowel Syndrome as Second-Line Treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ford AC; Wright-Hughes A; Alderson SL; Ow PL; Ridd MJ; Foy R; Bianco G; Bishop FL; Chaddock M; Cook H; Cooper D; Fernandez C; Guthrie EA; Hartley S; Herbert A; Howdon D; Muir DP; Nath T; Newman S; Smith T; Taylor CA; Teasdale EJ; Thornton R; Farrin AJ; Everitt HA;
    Lancet; 2023 Nov; 402(10414):1773-1785. PubMed ID: 37858323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial.
    Ki Cha B; Mun Jung S; Hwan Choi C; Song ID; Woong Lee H; Joon Kim H; Hyuk J; Kyung Chang S; Kim K; Chung WS; Seo JG
    J Clin Gastroenterol; 2012 Mar; 46(3):220-7. PubMed ID: 22157240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized double-blind, placebo-controlled trial to evaluate the safety and efficacy of live
    Srivastava S; Basak U; Naghibi M; Vijayakumar V; Parihar R; Patel J; Jadon PS; Pandit A; Dargad RR; Khanna S; Kumar S; Day R
    Gut Microbes; 2024; 16(1):2338322. PubMed ID: 38630015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. I.31, a new combination of probiotics, improves irritable bowel syndrome-related quality of life.
    Lorenzo-Zúñiga V; Llop E; Suárez C; Alvarez B; Abreu L; Espadaler J; Serra J
    World J Gastroenterol; 2014 Jul; 20(26):8709-16. PubMed ID: 25024629
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effectiveness and Safety of Multi-Strain Probiotic Preparation in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: A Randomized Controlled Study.
    Skrzydło-Radomańska B; Prozorow-Król B; Cichoż-Lach H; Majsiak E; Bierła JB; Kanarek E; Sowińska A; Cukrowska B
    Nutrients; 2021 Feb; 13(3):. PubMed ID: 33652763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Peppermint Oil in a Randomized, Double-Blind Trial of Patients With Irritable Bowel Syndrome.
    Weerts ZZRM; Masclee AAM; Witteman BJM; Clemens CHM; Winkens B; Brouwers JRBJ; Frijlink HW; Muris JWM; De Wit NJ; Essers BAB; Tack J; Snijkers JTW; Bours AMH; de Ruiter-van der Ploeg AS; Jonkers DMAE; Keszthelyi D
    Gastroenterology; 2020 Jan; 158(1):123-136. PubMed ID: 31470006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised, double-blind, placebo controlled multi-centre study to assess the efficacy, tolerability and safety of Enterosgel® in the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults.
    Kemppinen A; Howell C; Allgar V; Dodd M; Gregson J; Knowles C; McLaughlin J; Pandya P; Whorwell P; Markaryan E; Yiannakou Y
    Trials; 2020 Jan; 21(1):122. PubMed ID: 32000822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.